At Saince, we build the technological foundation that empowers providers to focus entirely on their patients. By seamlessly integrating artificial intelligence, cloud-native infrastructure, and deep system interoperability, we are eliminating inefficiencies and bringing clinical information, radiology, and hospital management into the modern era. We are not just a service provider—we are a high-tech innovation engine for the healthcare industry.

USA: 5490 McGinnis Village Place, Suite 116, Alpharetta, GA 30005.
+1 888 472 4623 | sales@saince.com
INDIA: Corporate Address: #6-3-1090, Ground Floor, Block B, TSR Towers, Raj Bhavan Road, Somajiguda, Hyderabad, Telangana 500082.
Registered Address: #202, Shatabdi Residency, Ramnagargundu, Hyderabad, Telangana 500044.
+91 40 6728 5555 | sales@saince.in
Contact Us
Address 5490 McGinnis Village Place, Suite 116, Alpharetta, GA 30005.
Follow Us

Clinical documentation, imaging and intelligence solutions.

Blog Details

Blogs
MRI features can predict response to neoadjuvant chemotherapy for breast cancer August 08, 2021

MRI features can predict response to neoadjuvant chemotherapy for breast cancer

The Czarnota Research Team investigated whether pre-treatment T2-weighted magnetic resonance imaging can be used to predict response to neoadjuvant chemotherapy in breast cancer.

Pre-treatment T2-weighted MRI texture features can predict NAC response with reasonable accuracy. The study examined T2 non-contrast images in predicting the treatment response to NAC. They intend to expand the current study cohort to include a higher number of patients to perform more robust validation strategies, including consideration of external validation from a different institution.

Read the full article:

https://www.news-medical.net/news/20210806/MRI-texture-features-can-predict-response-to-neoadjuvant-chemotherapy-in-patients-with-breast-cancer.aspx